bioengineer.org /1 month ago

Combination therapy improves heart failure measures in retrospective Chinese cohort

A retrospective study of 150 Chinese heart-failure patients found that adding dapagliflozin to sacubitril-valsartan was associated with better cardiac-function measures, lower biom...

Read source
pharmexec.com /1 month ago

<![CDATA[EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe]]>

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Onswik for Adults with Type 2 Diabetes ]]>

Read source
qchron.com /3 weeks ago

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U...

- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint.

Read source
drugs.com /2 weeks ago

GLP-1 Drugs Can Help Reverse Prediabetes, Researchers Report

WEDNESDAY, Nov. 4, 2026 — Cutting-edge weight-loss drugs like Ozempic and Zepbound are helping people reverse prediabetes and avoid heart attack and stroke more effectively than st...

Read source
biopharmadive.com /3 weeks ago

Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.